Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy.
about
Persistent androgen receptor addiction in castration-resistant prostate cancerManagement of patients with biochemical recurrence after local therapy for prostate cancerTargeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathwayCelecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.Pomegranate Extracts in the Management of Men's Urologic Health: Scientific Rationale and Preclinical and Clinical Data.Non-steroidal anti-inflammatory drugs in the treatment of genitourinary malignancies: focus on clinical data.A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer.Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers.NSAIDs Use and Reduced Metastasis in Cancer Patients: results from a meta-analysisAspirin improves outcome in high risk prostate cancer patients treated with radiation therapy.Regulation of bombesin-stimulated cyclooxygenase-2 expression in prostate cancer cells.A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer.Potential utility of cancer-specific biomarkers for assessing response to hormonal treatments in metastatic prostate cancer.Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs.Oxidative stress measured by urine F2-isoprostane level is associated with prostate cancerChange in PSA velocity is a predictor of overall survival in men with biochemically-recurrent prostate cancer treated with nonhormonal agents: combined analysis of four phase-2 trials.Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trialsAnti-inflammatory drugs, antioxidants, and prostate cancer prevention.Aspirin use after a prostate cancer diagnosis and cancer survival in a prospective cohort.Learning from failure--rationale and design for a study about discontinuation of randomized trials (DISCO study).Targeting of cytosolic phospholipase A2α impedes cell cycle re-entry of quiescent prostate cancer cells.A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancerWeekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II studyManagement of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directionsInhibition of Akt pathways in the treatment of prostate cancer.Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volumeRole of the prostaglandin pathway and the use of NSAIDs in genitourinary malignancies.TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer.Prognostic Value of Prostaglandin-endoperoxide Synthase 2 Polymorphisms in Prostate Cancer Recurrence after Radical ProstatectomyEndoplasmic reticulum stress: its role in disease and novel prospects for therapy.The biological basis for immunotherapy in patients with chronic myelogenous leukemia.Macrophage cathepsin K promotes prostate tumor progression in bone.Emerging drugs for prostate cancer.The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer.Treatment of men with rising prostate-specific antigen levels following radical prostatectomy.Radioimmunotherapy for B-cell non-hodgkin lymphomas.The strategies to control prostate cancer by chemoprevention approaches.Nonsteroidal anti-inflammatory drugs and prostatic diseasesThe activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way.Management Options for Biochemically Recurrent Prostate Cancer.
P2860
Q26777163-EE999037-12B5-42C7-A88C-7AF11ABF26A6Q26849220-9642D7C4-BF6D-41B5-9A2A-C1694461958DQ28382812-03B5695C-D0B0-41C8-B665-A0518227DBDFQ30521133-BF7EF855-786C-45B7-80F5-98CEFDBF350BQ30617117-B54410BE-ECC1-4C5F-857C-70814F3DACC0Q33304363-115DAE67-61E4-4A3F-B738-36610FA6EFDBQ33390657-B9C5F229-F5CB-4318-A22A-789198E59F89Q33561179-53199329-2F7E-4B55-AC65-E56F8AB0EEEAQ33687606-7CB2DCAE-70F8-460D-A019-55E2E945B8CEQ33727848-DD163308-F501-450A-B634-341866A67B4DQ33957249-19F6F100-185C-4B41-9B57-F16CE0FAE8DEQ34205971-262143ED-6CF8-4B7A-9FA9-DC76D516FC19Q34536729-799647D1-5484-45D5-BD1B-98007549372AQ34743086-8FC75D76-8995-4877-8A98-4BD845A59DB5Q34977627-BCF4F2A6-0392-4F61-B8EB-6CD6164F8FDEQ35070443-F81D38BC-9DA9-4D0D-98F2-C16495721565Q35656240-E3844D8F-55FA-4BD6-AC39-6540D911E463Q35775751-A64E815D-0D58-4D9E-9681-3B31778DCBB8Q36478226-6AE384A2-6134-4A23-AA82-90CC45C35FE5Q36483995-6D6650EA-EF1F-4994-B034-FD598C44EE2BQ36544125-C137F2A3-F86E-4556-82C4-35A7330A0623Q36546241-833E671A-B97A-4FE8-9ED6-A80F49493C75Q36611472-92631399-2ACD-4AE8-8C82-9D4727D06D01Q36760953-5FEA241A-5BFF-4326-A13C-C85772BCCF8DQ36807494-8980724A-1E43-48E6-B629-1C36508868A5Q37185428-0ABC1AA6-7700-4FF1-8EFD-E42C9067F6B1Q37202773-E201C4E6-0F06-4821-A767-ED76B0D96AC0Q37224581-1A20A069-6982-41CF-89AB-451D80AB8DE1Q37263499-F194B3DD-8B2D-43A8-8D20-22035EBED8E1Q37288073-F814925F-42FD-40C4-B1AD-93DA524E1D5FQ37428671-FF8BC03C-D7C6-437C-B7BE-F67EAC0029CFQ37554550-74911FAB-4E2F-49F5-A880-9D1506D704D4Q37570555-FF5F25B5-023A-4D6C-89FE-EA4F53ED6C08Q37623774-747BDE7A-FAD7-46A4-861A-4AFF74738594Q37821906-D80C79ED-8063-41CB-A880-7AD30A1B7902Q38019790-03E07334-4D60-41D6-94D1-E3AC9409075FQ38175776-A871FCA8-B647-45FE-B20D-C6B9DFAA4A53Q38217858-07311149-900B-4ED1-B9F7-27F818B0F843Q38370773-0AE41B7E-10B5-4EE0-8C6E-AA4EEBF44D56Q38691937-D3DAE1E8-98F4-4788-AABD-43385F476014
P2860
Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Celecoxib versus placebo for m ...... tomy and/or radiation therapy.
@ast
Celecoxib versus placebo for m ...... tomy and/or radiation therapy.
@en
type
label
Celecoxib versus placebo for m ...... tomy and/or radiation therapy.
@ast
Celecoxib versus placebo for m ...... tomy and/or radiation therapy.
@en
prefLabel
Celecoxib versus placebo for m ...... tomy and/or radiation therapy.
@ast
Celecoxib versus placebo for m ...... tomy and/or radiation therapy.
@en
P2093
P356
P1476
Celecoxib versus placebo for m ...... tomy and/or radiation therapy.
@en
P2093
Donald S Kaufman
Glenn J Bubley
Judith Manola
Matthew R Smith
P304
P356
10.1200/JCO.2005.03.7804
P407
P577
2006-06-01T00:00:00Z